Uncommon EGFR Mutations in Non–Small Cell Lung Cancer - Episode 9

Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

March 2, 2021

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

EP. 1: Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC

EP. 2: Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer

EP. 3: Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC

EP. 4: Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities

EP. 5: Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

EP. 6: Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

EP. 7: Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC

EP. 8: Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC

Now Viewing

EP. 9: Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

EP. 10: Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC

EP. 11: Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

EP. 12: Uncommon EGFR Mutations in Non–Small Cell Lung Cancer

Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the efficacy of mobocertinib (formerly TAK-788) in metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 20 insertion mutations.

Data from an ongoing phase 1/2 trial (NCT02716116) demonstrated an overall response rate of 26% per an independent review committee and 35% per investigator assessment with mobocertinib in previously treated patients with metastatic EGFR exon 20–mutated NSCLC. Notably, the trial evaluated mobocertinib in the second-line setting for patients who previously received platinum-based chemotherapy, says Spira.

Regarding safety, mobocertinib was associated with high rates of diarrhea and some mucositis, Spira explains. Although these adverse effects tended to be low grade, mobocertinib is an oral agent that is intended for long-term use. Therefore, even low-grade toxicities could be limiting, particularly in older patients or individuals with comorbidities, Spira concludes.